Replies to post #820355 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Investor082,

Thanks for reminding us about “BP” 😶

We are looking forward to more NEXT-GEN COMBO research & further research beyond GBM…

This PII combo clinical trial is one example that just posted an update on Feb 12th, 2026. Moffitt is included on its list of trial sites, & it’s funded by a rigorously peer-reviewed competitive grant awarded by the 🇺🇸U.S. DoD:


ASCO 2025


Both DCVax®-L & the polarized aDC1 platform are included in active PII combo trials with
Merck’s pembrolizmab & participants in those trials are being treated TODAY.

The forthcoming COMBO trial for ovarian cancer involves the polarized aDC1 platform too…

The NIH database entry for Dr. Kalinski’s previous grant award may provide insight into the potential design of the ovarian cancer combo trial:

🇺🇸U.S. National Institutes of Health Grants Database



Perhaps even more valuable than the funding itself, the validation that comes with a rigorously peer-reviewed grant award is immensely significant!



Dr. Kalinski




University of Pittsburgh Hillman Cancer Center



The Dava Oncology Breast Cancer Summit was a noteworthy event last August—deserved more attention. NWBO’s polarized aDC1 platform technology was featured, & combo with checkpoint blockade was highlighted!

Dr. Shipra Gandhi was the principal on the aDC1 combo trial NCT04348747 before joining the Winship Cancer Institute at Emory University. Dr. Sheheryar Kabraji is the current principal of the study, & he also attended the conference.

Starting Now: Cellular Therapies and Vaccine Strategies
Moderated by: Dr. Vinay Jain #DAVABreast pic.twitter.com/fl2E6KiHtB

— DAVA Oncology (@DAVAOnc) August 23, 2025

Starting Now: Novel Immune Checkpoint Approaches
Moderated by: @Dr_RShatsky @UCSDHealth #DAVABreast pic.twitter.com/MAopMWbirC

— DAVA Oncology (@DAVAOnc) August 23, 2025

Can we re-engage anti-HER2/3 immunity in brain-metastatic breast cancer? Dr. @gandhi_shipra from @WinshipAtEmory presents a dendritic cell vaccine + PD-1 combo approach in CNS disease (NCT04348747), with a novel Th1/CTL-driven strategy at #DAVABreast #BreastCancer pic.twitter.com/OTgEhph8CR

— DAVA Oncology (@DAVAOnc) August 21, 2025

Thanks @DAVAOnc for a great week full of new learning and connections and renewing old friendships https://t.co/4hxE4obErG

— Sheheryar Kabraji (@SKabrajiMD) August 25, 2025

ASCO 2025 Abstract

AI Fact-Checking

All foregoing comments relate exclusively to the topic of Northwest Biotherapeutics and its stock. Statements are made in the context of public discussion and are directed solely at the content of claims, forecasts, or interpretations presented therein. Any emphasis in tone or phrasing is used solely to highlight discrepancies, inconsistencies, unsupported conclusions, or areas where additional substantiation may be appropriate or requested in furtherance of the discussion. Nothing herein is intended as commentary on any individual participant, identity, or posting alias.